Chimeric antigen receptor (CAR) T therapy represents an exciting and promising modality for cancer treatment, evidenced by approvals of Kymriah and Yescarta. The potential of this new technology is massive. However, it is widely recognised that complex and lengthy manufacturing requirements for such adoptive cell therapies (ACT) limit widespread use. ImmTune Therapies is a biotechnology company focusing on a next-generation in vivo delivery protocol which will unlock the full potential of ACT for the treatment of cancer. The commercial development of an in vivo treatment represents a highly innovative opportunity to redefine how ACT is applied and will provide a great boost to these cell and gene therapies.